
Inflammatory processes drive AD both within and beyond the skin, leading to significant, cumulative life impacts. Early intervention has the potential to mitigate these impacts by altering the disease course.

Exploration of the shared mechanisms of itch across AD, PN, and CSU as well as the distinct ways itch manifests in each disease.

In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Mark Boguniewicz discusses the prevalence of food sensitization and food allergy in pediatric patients with AD, clarifying the difference between the two. Dr Boguniewicz also discusses the prevalence of other atopic comorbidities in children with AD

Matthew Zirwas, MD, is an American Board of Dermatology-certified physician. He is a nationally known expert who has been specializing in contact dermatitis, pruritus, atopic dermatitis, and seborrheic dermatitis for the last 20 years.

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation processes underlying pediatric asthma, atopic dermatitis, and eosinophilic esophagitis.

Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.

Co-Director of the Multidisciplinary Atopic Dermatitis Program | Rady Children's Hospital, San Diego | Associate Clinical Professor | UC San Diego School of Medicine, California, United States

In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga highlights the multidimensional burden of uncontrolled AD and how the various burdens contribute to Cumulative Life Course Impairment (CLCI).

Dr. Paller discusses factors influencing AD chronicity and comorbidities, focusing on disease severity, early onset, heredity, multiple allergies, and urban living as important in evaluating AD’s lasting effects on children.

Dr. Paller explores the multifaceted impact of AD, highlighting its association with various comorbidities such as food allergies, asthma, allergic rhinitis, and mental health disorders.

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel presents how systemic inflammation affects organ systems beyond the skin, and could potentially manifest as atopic and non-atopic comorbidities.